B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

(2010) Silvia Bosello et al.   ARTHRITIS RESEARCH & THERAPY

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

(2009) Alfiya Akhmetshina et al.   ARTHRITIS AND RHEUMATISM

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

(2009) Robert Lafyatis et al.   ARTHRITIS AND RHEUMATISM

Increased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis

(2009) Lorin E. Olson et al.   DEVELOPMENTAL CELL

CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma

(2008) Ayumi Yoshizaki et al.   AMERICAN JOURNAL OF PATHOLOGY

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

(2008) V Smith et al.   ANNALS OF THE RHEUMATIC DISEASES

CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model

(2008) Kazuhiro Komura et al.   ARTHRITIS AND RHEUMATISM

The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study

(2008) A. Soria et al.   DERMATOLOGY